---
document_datetime: 2026-01-12 14:02:59
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/hetronifly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: hetronifly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0735609
conversion_datetime: 2026-01-14 08:31:56.302254
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## HETRONIFLY

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 04/12/2025                          |                                             | SmPC and PL                      | SmPC new text Based on safety signals identified |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000291455                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2, 4.4 and 4.8 of SmPC in order to include myasthenia gravis and myasthenic syndrome to the list of adverse drug reactions (ADRs) with frequency 'rare', based on a signal assessment report. Additional warning and recommendations for treatment modifications are also included. The Package Leaflet is updated accordingly. The updated RMP version 1.4 has also been submitted.   |            |     | during routine pharmacovigilance activities, 'myasthenia gravis' and 'myasthenic syndrome' have been included as ADRs. Section 4.4 has been updated to include a warning advising patients to seek immediate medical attention if symptoms of myasthenia gravis and myasthenic syndrome occurs (e.g. muscle weakness and tiring easily). Section 4.2 has been updated to include recommendations for treatment modifications: in Grade 3 or 4 cases, treatment should be permanently discontinued, while in Grade 2 cases, treatment should be withheld.   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000301620 | This was an application for a group of variations. B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.f The scale for a biological/immunological medicinal product is increased / decreased without process change (e.g. duplication of line) - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.a Minor change in the manufacturing process - Accepted                                                                    | 03/11/2025 | N/A |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000272312   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - To update section 2 of the SmPC and section 2 of the package leaflet to include polysorbate 80 as an excipient as per the Excipients Guideline. - To update sections 4.2, 4.4, 4.5, 4.8, 5.2, 5.3 and 6.1 of the SmPC, annex IID, and section 4 of the package leaflet in order to implement changes proposed by member states Spain and Germany as part of the post-opinion linguistic review of the MAA application. - In addition, the MAH has taken the opportunity to update Part B of Annex II to revise the legal status of Hetronifly from \"special and restricted medical prescription\" to \"restricted medical prescription\" in order to align the PI with the RMP.   | 25/07/2025   |     | SmPC, Annex II and PL   |
|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|-------------------------|
| Variation type IB / EMA/VR/0000281029   | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a                                                                                                                                                                                                                                                                                                                                                                                                                                          | 11/07/2025   | N/A |                         |

<div style=\"page-break-after: always\"></div>

|                                          | starting material/intermediate - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation - Accepted   |            |                 |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|
| Variation type IA_IN / EMA/VR/0000266638 | This was an application for a group of variations. B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished                                                                                                                                                                                                                                                                                                                      | 05/05/2025 | Annex II and PL |

<div style=\"page-break-after: always\"></div>

|                                                         | product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging site - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not   |            |            |                        |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Marketing Authorisation Transfer - H / EMA/T/0000252778 | - Transfer of a marketing authorisation - transfer of marketing authorisation from Henlius Europe GmbH to Accord Healthcare S.L.U.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 26/02/2025 | 31/03/2025 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| PSUR / EMA/PSUR/0000282289   | - -   | Maintenance   |
|------------------------------|-------|---------------|